Abstract
Objective: To assess whether survival differences exist between patients undergoing immediate open repair vs surveillance with selective repair for 4.0- to 5.4-cm abdominal aortic aneurysms (AAAs) and whether these differences vary by diameter, within sexes, or overall. Patients and Methods: The study cohort included 2226 patients randomized to immediate repair or surveillance for the UK Small Aneurysm Trial (September 1, 1991, through July 31, 1998; follow-up, 2.6-6.9 years) or the Aneurysm Detection and Management trial (August 1, 1992, through July 31, 2000; follow-up, 3.5-8.0 years). Survival differences were assessed with proportional hazard models, adjusted for a comprehensive array of clinical and nonclinical risk factors. Interaction between treatment and AAA size was added to the model to assess whether the effect of immediate open repair vs surveillance varied by AAA size. Results: The adjusted analysis revealed no statistically significant survival difference between immediate open repair and surveillance patients (hazard ratio [HR], 0.99; 95% CI, 0.83-1.18; mean follow-up time, 1921 days for both study groups). This lack of treatment effect persisted when men (HR, 1.01; 95% CI, 0.84-1.21) and women (HR, 0.96; 95% CI, 0.49-1.86) were examined separately and did not vary by AAA size (P=.39 for the entire cohort and P=.24 for women). Conclusion: Immediate open repair offered no significant survival benefit, even in patients with the largest AAAs and highest risk of rupture. Because recent trials failed to find a survival benefit of immediate endovascular repair over surveillance for small asymptomatic AAAs, our findings suggest that the gray area of first-line management for these patients should be resolved in favor of surveillance.
Original language | English (US) |
---|---|
Pages (from-to) | 910-919 |
Number of pages | 10 |
Journal | Mayo Clinic Proceedings |
Volume | 88 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2013 |
Bibliographical note
Funding Information:Grant Support: The ADAM trial was supported by the Veterans Affairs Cooperative Studies Program, Department of Veterans Affairs Office of Research and Development, Washington, DC. The UKSAT was funded by the Medical Research Council and British Heart Foundation. This work was funded by Agency for Healthcare Research and Quality grant R01HS018576 . Additional funding was provided by the Bradley Family Endowment to Baylor Health Care System Foundation.